These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

524 related articles for article (PubMed ID: 34630403)

  • 1. γδ T Cells for Leukemia Immunotherapy: New and Expanding Trends.
    Barros MS; de Araújo ND; Magalhães-Gama F; Pereira Ribeiro TL; Alves Hanna FS; Tarragô AM; Malheiro A; Costa AG
    Front Immunol; 2021; 12():729085. PubMed ID: 34630403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent ex vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine release.
    Park JA; Santich BH; Xu H; Lum LG; Cheung NV
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Translating Unconventional T Cells and Their Roles in Leukemia Antitumor Immunity.
    de Araújo ND; Gama FM; de Souza Barros M; Ribeiro TLP; Alves FS; Xabregas LA; Tarragô AM; Malheiro A; Costa AG
    J Immunol Res; 2021; 2021():6633824. PubMed ID: 33506055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Dual Roles of Human γδ T Cells: Anti-Tumor or Tumor-Promoting.
    Li Y; Li G; Zhang J; Wu X; Chen X
    Front Immunol; 2020; 11():619954. PubMed ID: 33664732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential of gamma/delta T cells for solid tumor immunotherapy.
    Zhu D; Ren X; Xie W; Chen J; Liang S; Jiang M; Wang J; Zheng Z
    Front Immunol; 2024; 15():1466266. PubMed ID: 39253082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. γδ cell-based immunotherapy for cancer.
    Lo Presti E; Corsale AM; Dieli F; Meraviglia S
    Expert Opin Biol Ther; 2019 Sep; 19(9):887-895. PubMed ID: 31220420
    [No Abstract]   [Full Text] [Related]  

  • 7. Tumor hypoxia represses γδ T cell-mediated antitumor immunity against brain tumors.
    Park JH; Kim HJ; Kim CW; Kim HC; Jung Y; Lee HS; Lee Y; Ju YS; Oh JE; Park SH; Lee JH; Lee SK; Lee HK
    Nat Immunol; 2021 Mar; 22(3):336-346. PubMed ID: 33574616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD8
    Farhood B; Najafi M; Mortezaee K
    J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engineering the Bridge between Innate and Adaptive Immunity for Cancer Immunotherapy: Focus on γδ T and NK Cells.
    Morandi F; Yazdanifar M; Cocco C; Bertaina A; Airoldi I
    Cells; 2020 Jul; 9(8):. PubMed ID: 32707982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy Approaches Beyond PD-1 Inhibition: the Future of Cellular Therapy for Head and Neck Squamous Cell Carcinoma.
    Qureshi HA; Lee SM
    Curr Treat Options Oncol; 2019 Mar; 20(4):31. PubMed ID: 30874960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Editorial: γδ T Cells in Cancer.
    Coffelt SB; Kabelitz D; Silva-Santos B; Kuball J; Born W; Bank I
    Front Immunol; 2020; 11():602411. PubMed ID: 33329597
    [No Abstract]   [Full Text] [Related]  

  • 12. Renal Cell Carcinoma-Infiltrating CD3
    Lee HW; Park C; Joung JG; Kang M; Chung YS; Oh WJ; Yeom SY; Park WY; Kim TJ; Seo SI
    Curr Issues Mol Biol; 2021 May; 43(1):226-239. PubMed ID: 34071865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD19-specific triplebody SPM-1 engages NK and γδ T cells for rapid and efficient lysis of malignant B-lymphoid cells.
    Schiller CB; Braciak TA; Fenn NC; Seidel UJ; Roskopf CC; Wildenhain S; Honegger A; Schubert IA; Schele A; Lämmermann K; Fey GH; Jacob U; Lang P; Hopfner KP; Oduncu FS
    Oncotarget; 2016 Dec; 7(50):83392-83408. PubMed ID: 27825135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy: enhancing the efficacy of this promising therapeutic in multiple cancers.
    Inthagard J; Edwards J; Roseweir AK
    Clin Sci (Lond); 2019 Jan; 133(2):181-193. PubMed ID: 30659159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TIM-3 blockade combined with bispecific antibody MT110 enhances the anti-tumor effect of γδ T cells.
    Guo Q; Zhao P; Zhang Z; Zhang J; Zhang Z; Hua Y; Han B; Li N; Zhao X; Hou L
    Cancer Immunol Immunother; 2020 Dec; 69(12):2571-2587. PubMed ID: 32588076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. γδ T cells in cancer immunotherapy.
    Zou C; Zhao P; Xiao Z; Han X; Fu F; Fu L
    Oncotarget; 2017 Jan; 8(5):8900-8909. PubMed ID: 27823972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. γδ T Cells in Tumor Microenvironment.
    Imbert C; Olive D
    Adv Exp Med Biol; 2020; 1273():91-104. PubMed ID: 33119877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NKG2A expression identifies a subset of human Vδ2 T cells exerting the highest antitumor effector functions.
    Cazzetta V; Bruni E; Terzoli S; Carenza C; Franzese S; Piazza R; Marzano P; Donadon M; Torzilli G; Cimino M; Simonelli M; Bello L; Villa A; Tan L; Ravens S; Prinz I; Supino D; Colombo FS; Lugli E; Marcenaro E; Vivier E; Della Bella S; Mikulak J; Mavilio D
    Cell Rep; 2021 Oct; 37(3):109871. PubMed ID: 34686325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rescuing lymphocytes from HLA-G immunosuppressive effects mediated by the tumor microenvironment.
    Wu D; Kuiaste I; Moreau P; Carosella E; Yotnda P
    Oncotarget; 2015 Nov; 6(35):37385-97. PubMed ID: 26460949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue-resident memory CD8
    Wang T; Shen Y; Luyten S; Yang Y; Jiang X
    Pharmacol Res; 2020 Sep; 159():104876. PubMed ID: 32422340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.